



LKT Laboratories, Inc.

SB-590885

Phone: 888-558-5227

651-644-8424

Fax: 888-558-7329

Email: [getinfo@lktlabs.com](mailto:getinfo@lktlabs.com)

Web: [lktlabs.com](http://lktlabs.com)

## Product Information

**Product ID** S0459

**CAS No.** 405554-55-4

**Chemical Name** (E)-5-(2-(4-(2-(dimethylamino)ethoxy)phenyl)-4-(pyridin-4-yl)-1H-imidazol-5-yl)-2,3-dihydroinden-1-one oxime

**Synonym**

**Formula** C<sub>27</sub>H<sub>27</sub>N<sub>5</sub>O<sub>2</sub>

**Formula Wt.** 453.54

**Melting Point**

**Purity** ≥97%

**Solubility** DMSO 5 mg/mL (11.02 mM)


Water Insoluble

Ethanol Insoluble

**Store Temp** -20° C

**Ship Temp** Ambient

**Description** SB-590885 is a triarylimidazole that selectively inhibits Raf kinase and is a particularly potent inhibitor of B-Raf. SB-590885 exhibits anticancer chemotherapeutic activity through its ability to stabilize the oncogenic B-Raf kinase domain in an active configuration, therefore inhibiting downstream MAPK activation. SB-590885 also limits tissue damage after cerebral ischemia, displaying neuroprotective benefit.



**Bulk quantities available upon request**

Product ID	Size
S0459	1 mg
S0459	5 mg

**References** Ahnstedt H, Säveland H, Nilsson O, et al. Human cerebrovascular contractile receptors are upregulated via a B-Raf/MEK/ERK-sensitive signaling pathway. *BMC Neurosci.* 2011 Jan 11;12:5. PMID: 21223556.

King AJ, Patrick DR, Batorsky RS, et al. Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. *Cancer Res.* 2006 Dec 1;66(23):11100-5. PMID: 17145850.

**Caution:** This product is intended for laboratory and research use only. It is not for human or drug use.